Home > Insider Trading > Filing (0000904454-20-000592)

Filing Details

Accession Number:: 0000904454-20-000592
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-08-20 18:25:27
Reporting Period:: 2020-08-18

Accepted Time:: 2020-08-20 18:25:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1468534	John Trizzino	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	Evp, Cbo And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-08-18	11,249	$99.80	16,336	No	4	M	Direct
Common Stock	Acquisiton	2020-08-18	5,855	$27.00	22,191	No	4	M	Direct
Common Stock	Acquisiton	2020-08-18	1,952	$27.00	24,143	No	4	M	Direct
Common Stock	Acquisiton	2020-08-18	13,322	$27.60	37,465	No	4	M	Direct
Common Stock	Acquisiton	2020-08-18	10,410	$46.00	47,875	No	4	M	Direct
Common Stock	Disposition	2020-08-18	776	$142.85	47,099	No	4	S	Direct
Common Stock	Disposition	2020-08-18	300	$143.99	46,799	No	4	S	Direct
Common Stock	Disposition	2020-08-18	4,900	$146.21	41,899	No	4	S	Direct
Common Stock	Disposition	2020-08-18	8,094	$146.95	33,805	No	4	S	Direct
Common Stock	Disposition	2020-08-18	9,101	$147.99	24,704	No	4	S	Direct
Common Stock	Disposition	2020-08-18	6,600	$149.08	18,104	No	4	S	Direct
Common Stock	Disposition	2020-08-18	1,800	$149.83	16,304	No	4	S	Direct
Common Stock	Disposition	2020-08-18	4,010	$150.85	12,294	No	4	S	Direct
Common Stock	Disposition	2020-08-18	4,199	$152.22	8,095	No	4	S	Direct
Common Stock	Disposition	2020-08-18	1,708	$153.16	6,387	No	4	S	Direct
Common Stock	Disposition	2020-08-18	1,300	$153.95	5,087	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	11,249	$0.00	11,249	$99.80
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	5,855	$0.00	5,855	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	1,952	$0.00	1,952	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	13,322	$0.00	13,322	$27.60
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	10,410	$0.00	10,410	$46.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2026-03-15	No	4	M	Direct
394	2026-11-14	No	4	M	Direct
4,298	2026-11-14	No	4	M	Direct
6,677	2027-12-15	No	4	M	Direct
14,589	2028-12-13	No	4	M	Direct

Footnotes

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.31 to $143.19, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.99 to $144.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.52 to $146.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.52 to $147.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.52 to $148.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.52 to $149.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.59 to $150.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.59 to $151.35, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.76 to $152.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.78 to $153.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.81 to $154.25, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.